Market capitalization | $189.52m |
Enterprise Value | $168.15m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 8.35 |
P/S ratio (TTM) P/S ratio | 9.41 |
P/B ratio (TTM) P/B ratio | 9.13 |
Revenue growth (TTM) Revenue growth | -22.51% |
Revenue (TTM) Revenue | $20.14m |
As a Free StocksGuide user, you can view scores for all 6,908 stocks worldwide.
4 Analysts have issued a MediWound Ltd. forecast:
4 Analysts have issued a MediWound Ltd. forecast:
Dec '23 | |
Current assets | 50 50 |
Fixed assets | 17 17 |
Total Assets | 66 66 |
Dec '23 | |
Equity | 32 32 |
Debt capital | 27 27 |
Total Capital | 59 59 |
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
MediWound Ltd. is a biopharmaceutical company engaging in the development, manufacture, and commercialization of products to address needs in the fields of severe burns, chronic wounds, and other hard-to-heal wounds. Its product is NexoBrid. The company was founded by Lior Rosenberg and Marian Gorecki in 2001 and is headquartered in Yavne, Israel.
Head office | Israel |
CEO | Ofer Gonen |
Employees | 100 |
Founded | 2000 |
Website | www.mediwound.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.